Following a successfully phase III clinical study [165], the FDA approved the first PI3K inhibitor, Piqray (alpelisib), for breast cancer patients with advanced disease and where their tumors have the PIK3CA mutation and are hormone receptor (HR) positive and HER2 negative in 2019. This evidence concerns the gene PIK3CA and breast cancer.